Related Experiment Videos

Selective decontamination of the digestive tract as an infection-control measure in intensive care unit patients

D J Occhipinti1, G Itokazu, L H Danziger

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago 60612.

Pharmacotherapy
|January 1, 1992
PubMed

Insights

Selective gastrointestinal decontamination using topical antibiotics effectively reduces infections in intensive care unit (ICU) patients, particularly gram-negative respiratory infections. This method shows promise for reducing nosocomial infections without increasing antimicrobial resistance.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Microbiology

Background:

  • Infections contribute significantly to morbidity and mortality in intensive care unit (ICU) patients.
  • Conventional infection control measures have limited success in reducing nosocomial infections.
  • Selective gastrointestinal decontamination (SGID) aims to reduce infection by targeting intestinal colonization.

Purpose of the Study:

  • To evaluate the efficacy of selective gastrointestinal decontamination in reducing infections among ICU patients.
  • To assess the impact of SGID on colonization by pathogenic microorganisms.
  • To investigate the development of antimicrobial resistance associated with SGID.

Main Methods:

  • Administration of topical nonabsorbable antibiotics to selectively target gram-negative organisms and yeasts in the gastrointestinal tract.
  • Monitoring of patient colonization and infection rates.
  • Assessment of antimicrobial resistance patterns.

Main Results:

  • SGID effectively reduced intestinal colonization and infection rates in the majority of clinical trials.
  • Significant reductions in gram-negative respiratory infections were observed.
  • Antimicrobial resistance was not widely documented, though follow-up periods were limited.

Conclusions:

  • Selective gastrointestinal decontamination is an effective strategy for reducing infections in ICU patients.
  • The primary benefit is observed in reducing gram-negative respiratory infections.
  • Patients without significant underlying disease appear to benefit most; SGID does not alter overall mortality.

Related Concept Videos